North Africa Non-Invasive Prenatal Testing Market, By Application (Trisomy, Microdeletion Syndrome, Sex Chromosome Abnormalities, Others), By End User (Hospitals, Diagnostic Centers & Independent Laboratories), By Country (Egypt, Algeria, Morocco, and Rest of North Africa) is estimated to be valued at US$ 2,796 Mn in 2021 and is expected to exhibit a CAGR of 8.7% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
North Africa non-invasive prenatal testing market is expected to significantly grow in the near future, owing to the presence of major market players in the country. These market players are focused on the development of novel treatment options with the potential to gain regulatory approvals. They are also adopting inorganic growth strategies such as approvals, collaborations, and partnerships to strengthen their therapeutics portfolio.
For instance, in February 2018, Illumina Inc., a biotechnology company, signed a value-based contract with Harvard Pilgrim Health Care, a non-profit health services company. This agreement is aimed at enhancing patient access and the reimbursement of next-generation sequencing for non-invasive prenatal testing (NIPT).
North Africa Non-Invasive Prenatal Testing Market – Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 outbreak in December 31, 2019, the disease has spread to over 100 countries and the World Health Organization (WHO) has declared it a public health emergency on March 11, 2020. The outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to the coronavirus were reported till December 07, 2021, across the globe.
Increase in maternal depression, maternal deaths, stillbirth, and ruptured ectopic pregnancies have worsened the global maternal and fetal outcomes during the COVID-19 pandemic. As per the National Library of Medicine, there were 42 studies involving 439, 549 women who were pregnant globally. The COVID-19 was associated with preterm birth and stillbirth as compared with no SARS-CoV-2 infection during pregnancy. When compared with mild COVID-19 infection, it was strongly related with preterm birth, gestational diabetes, and low birth weight.
Browse 16 Market Data Tables and 18 Figures spread through 126 Pages and in-depth TOC on “North Africa Non-Invasive Prenatal Testing Market”, By Application (Trisomy, Microdeletion Syndrome, Sex Chromosome Abnormalities, and Others), By End User (Hospitals, Diagnostic Centers & Independent Laboratories), and By Country (Egypt, Algeria, Morocco, and Rest of North Africa)
To know the latest trends and insights prevalent in the North Africa Non-Invasive Prenatal Testing Market, click the link below:
Key market players are focused on adopting various inorganic growth strategies such as collaborations, partnerships, and agreements to expand their product offerings in the market.
For instance, in March 2018, Natera, Inc., a global leader in cell-free DNA, partnered with QIAGEN N.V., a technology provider company, to develop assays which would be used in QIAGEN’s GeneReader Next-generation sequencing system.
Key Takeaways of North Africa Non-Invasive Prenatal Testing Market:
- North Africa non-invasive prenatal testing market is expected to exhibit a CAGR of 8.7% over the forecast period, owing to increasing research and development to invent advanced non-invasive prenatal tests.
- Among application, trisomy segment is expected to hold the largest market share over the forecast period. For instance, in February 2018, Premaitha Health Plc, subsidiary of Yourgene Health Plc, an international molecular diagnostics group, signed an agreement with a new partner (name undisclosed) to offer the IONA test over the Egypt. IONA test is a prenatal screening test that detects the possibility of fetus getting affected by Down’s syndrome.
- Companies operating in North Africa non-invasive prenatal testing market include Illumina, Inc., Eurofins Scientific, PerkinElmer, Inc., F. Hoffmann-La Roche AG, Natera, Inc., Yourgene Health Plc., Laboratory Corporation of America Holdings (LabCorp), BGI Group, and Quest Diagnostics Incorporated
